Equity
€267,815 ▲ 59.8%
Equity rose in 2025 from €167,593 to €267,815.
MILAMED
Lifetime
20 annual accounts with figures on one time axispeak €179,160 (2025)
€179,160▲ 4.1%
lowest -€27,049 (2009)
€100,222▲ 17.6%
peak €267,815 (2025)
€267,815▲ 59.8%
€128,304▲ 70.4%
Board2 names since 2005
2 directors and 1 other
Documentsfilings and deeds
01-07-202630 days before the deadline
2025micro format
Equity from €167,593 to €267,815Debts from €75,275 to €128,304Cash from €109,160 to €263,548
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 31,386 companies had the same profile as MILAMED has now. Each dot stands for 79 companies, two years later.
93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,386 companies, not a prediction for MILAMED. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0874998693
Changes of role: (director) and (director)
Director discharge: (manager) · Director discharge: (manager) · General meeting of 08-11-2023 · Gazette deed
Reappointments: (manager) and (manager)
General meeting of 24-06-2016 · Gazette deed
Incorporation
published on 19-07-2005 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MILAMED Woluwe-Saint-Pierre | €396,118 | €179,160 | 67.6% | - |
| DRUEZ SAUSSOY OBE Auderghem | €385,015 | €159,019 | 95.3% | - |
| MC VAN MOLLEM Beaumont | €394,327 | €181,322 | 85.2% | - |
| Docteur Franck Pieron Médical Sprimont | €404,980 | €186,610 | 91.5% | - |
| CABINET MEDICAL DU DOCTEUR FINIANOS Chaudfontaine | €393,676 | €188,987 | 24.7% | - |
| Dr. Coenen, Anesthesie Geraardsbergen | €394,904 | €184,077 | 81.5% | - |
| GYNAECOLOGIE LOKEREN Lokeren | €421,395 | €189,153 | 4.4% | 0 |
These companies have the same main activity as MILAMED: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €385,000 and €421,000, founded between 2004 and 2007.
Official details
Source: KBO- Status
- Active since 11-07-2005Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.307.521.4191950 Kraainem, since 11-07-2005
- Financial year end
- 31 December
- Peppol
- Reachable since 08-10-2025
Annual accounts 2025
- €396,118▲ 63.1%
- Filing
- Filed on 01-07-2026, 30 days before the end of the filing period
Insights on MILAMED
MILAMED files the micro format. That format states no turnover. The gross margin rose from €63,518 in 2006 to €179,160 in 2025.
The balance sheet grew most from 2007 to 2009 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MILAMED
- What is the company number of MILAMED?
- The company number of MILAMED is 0874.998.693. The VAT number is the same number with BE in front: BE 0874.998.693.
- Where is MILAMED based?
- The registered office is at St-Michielskollegestraat 42, 1150 Woluwe-Saint-Pierre.Company details
- What does MILAMED do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of MILAMED?
- MILAMED is a private limited company (BV).
- When was MILAMED founded?
- MILAMED was founded on 11-07-2005.
- Is MILAMED still active?
- Yes, MILAMED is an active enterprise in the KBO register.
- How many employees does MILAMED have?
- MILAMED had an average of 1 full-time equivalents in financial year 2023, according to the filed annual accounts.Financials
- What is the turnover of MILAMED?
- The turnover in financial year 2025 is ≈ €330,000. This figure is estimated from the gross margin of €179,160 and 40 comparable companies (NACE 86220). It probably lies between €280,000 and €440,000.
- Is MILAMED profitable?
- In financial year 2025, MILAMED made a profit of €100,222.
- Where can I find the annual accounts of MILAMED?
- MILAMED filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MILAMED due?
- MILAMED must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.